Particularly important, in the experiment of the allogeneic intracranial orthotopic GBM model, deguelin showed the ability to inhibit tumor growth and inhibit GBM angiogenesis by inhibiting the CCL2/NF-κB pathway in vivo. The gene discussed is NFKB1; the disease is glioblastoma.